Adenocarcinomas News and Research

RSS

Novel HER2 mutation identified in familial lung adenocarcinomas

Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas.

24 Jan 2014

Overdiagnosis concerns raised for CT lung cancer screening

People participating in any future computed tomography lung cancer screening program would face a significant risk for overdiagnosis, US researchers caution in JAMA Internal Medicine.

22 Jan 2014

ATN-224 inhibitor reduces tumor sizes in mouse model of lung adenocarcinoma

Many cancers have adapted to cope with high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1, is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy.

3 Dec 2013

Hologic's Aptima HPV 16 18/45 genotype assay gets FDA approval for use on Panther system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration has approved the Aptima HPV 16 18/45 genotype assay for use on the Company's fully automated Panther system.

From Hologic, Inc. 8 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

EZH2 protein may aid prognostication in resected NSCLC

A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe.

30 Oct 2013

Complement protein holds diagnostic, prognostic promise in lung cancer

A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests.

28 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

Protein pair may be prognostic biomarker for identifying smoking-related lung cancers

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.

20 Sep 2013

Assay aids ALK fusion detection in lung adenonocarcinoma

A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.

6 Sep 2013

Study compares spectrum of cancer-related gene mutations in two common types of cervical cancer

A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type's molecular idiosyncrasies.

26 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

8 Aug 2013

Study reveals nearly 40% of tumors are caused by viruses

The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses.

6 Aug 2013

Prolonged exposure to low levels of air pollution boosts lung cancer risk

Prolonged exposure to particulate air pollution increases the risk of lung cancer (particularly adenocarcinoma) even at levels below the European Union limit values, according to one of the largest studies of its kind published in The Lancet Oncology.

11 Jul 2013

Study shows disrupted micronuclei may prove to be a valuable tool for detecting cancer

Scientists studying cancer development have known about micronuclei for some time. These erratic, small extra nuclei, which contain fragments or whole chromosomes that were not incorporated into daughter cells after cell division, are associated with specific forms of cancer and are predictive of poorer prognosis.

10 Jul 2013

Disrupted micronuclei might play more active role in carcinogenesis, new study finds

9 Jul 2013

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors.

26 Jun 2013

Study may help diagnose endometrial cancer and lead to new drug development

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.

2 May 2013